Angiotech and Conor settle
This article was originally published in The Gray Sheet
Executive Summary
Angiotech reaches "favorable" agreement with Johnson & Johnson/Conor Medsystems Sept. 17 to settle all patent litigation ongoing since 2005 related to its paclitaxel-eluting stent technology. Angiotech licenses the patents in question exclusively to Boston Scientific for its Taxus stent. Johnson & Johnson discontinued development of the patent-relevant CoStar paclitaxel-eluting stent and terminated sales of the product overseas in May following disappointing trial results (1"The Gray Sheet" May 14, 2007, p. 9). The settlement covers all ongoing litigation in the UK, the Netherlands and Australia (2"The Gray Sheet" Jan. 22, 2007, p. 12)
You may also be interested in...
Failure Of J&J/Conor’s CoStar Stent Trial Sets Program Back Up To Four Years
Johnson & Johnson's Conor Medsystems unit will discontinue development of its CoStar paclitaxel-eluting coronary stent and terminate sales of the device overseas following the failure of the firm's CoStar II U.S. pivotal study
Courts In Netherlands And UK Differ In Conor/Angiotech Patent Dispute
Conor Medsystems and Boston Scientific are both claiming small victories in their ongoing patent dispute related to paclitaxel-eluting stent technology after a Dutch court ruled in favor of Boston Scientific during the same week that a United Kingdom court sided with Conor
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”